LVTX Annual Cash & Cash Equivalents
$44.23 M
-$56.10 M-55.92%
31 December 2023
Summary:
As of January 20, 2025, LVTX annual cash & cash equivalents is $44.23 million, with the most recent change of -$56.10 million (-55.92%) on December 31, 2023. During the last 3 years, it has risen by +$28.41 million (+179.62%). LVTX annual cash & cash equivalents is now -55.92% below its all-time high of $100.33 million, reached on December 31, 2022.LVTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LVTX Quarterly Cash And Cash Equivalents
$26.96 M
-$8.12 M-23.15%
30 September 2024
Summary:
As of January 20, 2025, LVTX quarterly cash and cash equivalents is $26.96 million, with the most recent change of -$8.12 million (-23.15%) on September 30, 2024. Over the past year, it has dropped by -$35.70 million (-56.97%). LVTX quarterly cash and cash equivalents is now -82.93% below its all-time high of $157.96 million, reached on March 31, 2021.LVTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LVTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -55.9% | -57.0% |
| 3 y3 years | +179.6% | -57.0% |
| 5 y5 years | +502.8% | -57.0% |
LVTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.9% | at low | -73.2% | at low |
| 5 y | 5-year | -55.9% | +502.8% | -82.9% | +70.5% |
| alltime | all time | -55.9% | +502.8% | -82.9% | +70.5% |
LAVA Therapeutics NV Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $26.96 M(-23.2%) |
| June 2024 | - | $35.09 M(-18.8%) |
| Mar 2024 | - | $43.19 M(-2.4%) |
| Dec 2023 | $44.23 M(-55.9%) | $44.23 M(-29.4%) |
| Sept 2023 | - | $62.66 M(-28.5%) |
| June 2023 | - | $87.61 M(-12.9%) |
| Mar 2023 | - | $100.60 M(+0.3%) |
| Dec 2022 | $100.33 M | $100.33 M(+56.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $64.33 M(-15.2%) |
| June 2022 | - | $75.87 M(-11.5%) |
| Mar 2022 | - | $85.72 M(-5.7%) |
| Dec 2021 | $90.87 M(+474.5%) | $90.87 M(-9.5%) |
| Sept 2021 | - | $100.36 M(-34.3%) |
| June 2021 | - | $152.74 M(-3.3%) |
| Mar 2021 | - | $157.96 M(+898.6%) |
| Dec 2020 | $15.82 M(+115.6%) | $15.82 M |
| Dec 2019 | $7.34 M | - |
FAQ
- What is LAVA Therapeutics NV annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV annual cash & cash equivalents year-on-year change?
- What is LAVA Therapeutics NV quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV quarterly cash and cash equivalents year-on-year change?
What is LAVA Therapeutics NV annual cash & cash equivalents?
The current annual cash & cash equivalents of LVTX is $44.23 M
What is the all time high annual cash & cash equivalents for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high annual cash & cash equivalents is $100.33 M
What is LAVA Therapeutics NV annual cash & cash equivalents year-on-year change?
Over the past year, LVTX annual cash & cash equivalents has changed by -$56.10 M (-55.92%)
What is LAVA Therapeutics NV quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LVTX is $26.96 M
What is the all time high quarterly cash and cash equivalents for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high quarterly cash and cash equivalents is $157.96 M
What is LAVA Therapeutics NV quarterly cash and cash equivalents year-on-year change?
Over the past year, LVTX quarterly cash and cash equivalents has changed by -$35.70 M (-56.97%)